BG Medicine Named To Russell 3000 Investment Index - Gilde Healthcare

BG Medicine Named To Russell 3000 Investment Index

April 1, 2011

WALTHAM, Mass., (GLOBE NEWSWIRE) – BG Medicine, Inc. (Nasdaq:BGMD) today announced that it has been added to the Russell 3000® Index, which measures the performance of the 3,000 largest publicly-traded U.S. companies based on total market capitalization. The Russell 3000 Index is constructed to provide a comprehensive barometer of the broad market and is reconstituted annually to capture new and growing companies.

“Following our initial public offering on February 4, 2011, we are very pleased to be added to the Russell 3000 Index,”

said Pieter Muntendam, M.D., president and chief executive officer of BG Medicine.

“Our inclusion in this index provides additional visibility for BG Medicine in the investment community as many investors rely on the Russell indices as part of their investment strategy.”

About BG Medicine

BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine recently launched the galectin-3 test for use in patients with heart failure. The galectin-3 test is the first novel blood test for cardiac disease cleared by the FDA in five years. For additional information about BG Medicine and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com.

About Gilde Healthcare Partners

Netherlands-based Gilde Healthcare Partners (www.gildehealthcare.nl) is a transatlantic venture and growth capital firm focused on private healthcare technologies and services. It has over €400 million under management and is actively looking to lead new investments in therapeutics, diagnostics, medical devices and services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €15 million in a single portfolio company. By investing in companies with clear achievable business models, Gilde has used its financial resources and network to create significant value for both its investors and the entrepreneurs it backs. For a list of Gilde’s portfolio companies please visit the website.

Gilde Healthcare raises €600 million to invest in healthcare innovation

A balanced mix of international investors commits €600 million to Gilde Healthcare Venture&Growth VI, a transatlantic investment fund Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its...
April 19, 2023

Gilde Healthcare portfolio company Moximed obtains FDA Market Authorization of the MISHA™ Knee System for People Suffering from Knee Osteoarthritis

Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement MISHA Knee System is implanted during an outpatient procedure; it's the first and only device of...
April 13, 2023

Gilde Healthcare company Adcendo announces extension of series A financing to EUR 82M to develop its first-in-class ADC pipeline

Gilde Healthcare portfolio company Adcendo Aps (‘Adcendo’), focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful completion of a Series...
April 4, 2023